MAPT and Alzheimer disease: A critical difference between our studies is that the previous study13 did not examine CSF biomarkers or any measure of ptau217, which is a sensitive marker for altered tau metabolism in Alzheimer’s disease.56 Another difference is that all the PRSs in Yang et al. 13 were constructed by excluding the APOE region SNPs.